Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in Systemic Lupus Erythematosus (CHABLIS 7.5)
NCT02514967Phase 3Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of blisibimod in systemic lupus erythematosus (SLE), sponsored by Anthera Pharmaceuticals, Inc.. Started Jun 2016; status: terminated.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02514967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514967.